Laxy Michael, Stark Renée, Meisinger Christa, Kirchberger Inge, Heier Margit, von Scheidt Wolfgang, Holle Rolf
Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany ; German Center for Diabetes Research, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Helmholtz Zentrum München, Institute of Health Economics and Health Care Management, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
Diabetol Metab Syndr. 2015 Sep 17;7:77. doi: 10.1186/s13098-015-0065-9. eCollection 2015.
Although the population-based German disease management programs (DMPs) for diabetes mellitus (DM) and coronary heart disease (CHD) are among the biggest worldwide, evidence on the effectiveness of these programs is still inconclusive or missing, particularly for high risk patients with comorbidities. The objective of this study was therefore to analyze the impact of DMPs on process and outcome parameters in patients with both, type 2 DM and CHD.
Analyses are based on two postal surveys of patients from the KORA myocardial infarction registry (southern Germany) with type 2 DM and on two postal validation studies with patients' general physicians (2006, n = 312 and 2011, n = 212). The association between DMP enrollment (being enrolled in either DMP-DM or DMP-CHD) and guideline care (defined by several process indicators) at baseline (2006) and its development until follow-up (2011) was analyzed using logistic regression models accounting for the repeated measurements structure. The impact of DMP enrollment/guideline care on cumulated (quality-adjusted) life years ((QA)LYs) over a 4-year time horizon (2006-2010) was assessed using multiple linear regression methods. Logistic regression models were applied to analyze the association between DMP status and patient self-management at follow-up.
Being enrolled in a DMP was associated with better guideline care at baseline [OR = 2.3 (95 % CI 1.27-4.03)], but not at follow-up [OR = 0.80 (95 % CI 0.40-1.58); p value for time-interaction <0.01]. DMP enrollment was not significantly [+0.15 LYs (95 % CI -0.07, 0.37); +0.06 QALYs (95 % CI -0.15, 0.26)], but treatment according to guideline care significantly [+0.40 LYs (95 % CI 0.21-0.60); +0.28 QALYs (95 % CI 0.10-0.45)] associated with higher (quality-adjusted) survival over the 4-year follow-up period. DMP enrollees further reported a somewhat better self-management than patients not being enrolled into a DMP.
The results of this study concerning the effectiveness of DMPs in patients with DM and CHD are mixed, but are weakly in favor of DMPs. However, we found a clear positive impact of guideline care on quality adjusted survival in this patient group. The development of the association between DMP enrollment and guideline care over the follow-up time indicates some external effects, which should be the subject of further investigations.
尽管德国基于人群的糖尿病(DM)和冠心病(CHD)疾病管理项目(DMPs)是全球规模最大的项目之一,但这些项目有效性的证据仍然不确凿或缺失,尤其是对于患有合并症的高危患者。因此,本研究的目的是分析DMPs对2型糖尿病和冠心病患者的过程及结局参数的影响。
分析基于对来自德国南部KORA心肌梗死登记处的2型糖尿病患者进行的两次邮寄调查,以及对患者的全科医生进行的两次邮寄验证研究(2006年,n = 312;2011年,n = 212)。使用考虑重复测量结构的逻辑回归模型,分析基线时(2006年)DMP注册(注册参加DMP-DM或DMP-CHD)与指南护理(由多个过程指标定义)之间的关联及其到随访时(2011年)的发展情况。使用多元线性回归方法评估DMP注册/指南护理对4年时间范围内(2006 - 2010年)累积(质量调整)生命年((QA)LYs)的影响。应用逻辑回归模型分析随访时DMP状态与患者自我管理之间的关联。
参加DMP与基线时更好的指南护理相关[比值比(OR)= 2.3(95%置信区间1.27 - 4.03)],但随访时并非如此[OR = 0.80(95%置信区间0.40 - 1.58);时间交互作用的p值<0.01]。DMP注册没有显著影响[+0.15生命年(95%置信区间 - 0.07,0.37);+0.06质量调整生命年(95%置信区间 - 0.15,0.26)],但按照指南护理进行治疗有显著影响[+0.40生命年(95%置信区间0.21 - 0.60);+0.28质量调整生命年(95%置信区间0.10 - 0.45)],与4年随访期内更高的(质量调整)生存率相关。DMP注册者报告的自我管理也比未参加DMP的患者略好。
本研究关于DMPs对糖尿病和冠心病患者有效性的结果喜忧参半,但略倾向于DMPs。然而,我们发现指南护理对该患者群体的质量调整生存率有明显的积极影响。随访期间DMP注册与指南护理之间关联的发展表明存在一些外部效应,这应是进一步研究的主题。